| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 46 | 2026 | 532 | 11.720 |
Why?
|
| Buprenorphine | 22 | 2025 | 199 | 7.680 |
Why?
|
| Opiate Substitution Treatment | 34 | 2026 | 226 | 6.840 |
Why?
|
| Substance-Related Disorders | 43 | 2023 | 758 | 6.720 |
Why?
|
| Substance Abuse Treatment Centers | 28 | 2020 | 104 | 3.920 |
Why?
|
| Prisoners | 11 | 2026 | 180 | 3.900 |
Why?
|
| Methadone | 20 | 2025 | 140 | 2.940 |
Why?
|
| Analgesics, Opioid | 19 | 2025 | 532 | 2.880 |
Why?
|
| Drug Overdose | 7 | 2024 | 123 | 2.560 |
Why?
|
| Crime | 12 | 2017 | 57 | 2.320 |
Why?
|
| Health Services Accessibility | 11 | 2026 | 603 | 2.110 |
Why?
|
| Adult | 84 | 2026 | 17575 | 2.060 |
Why?
|
| Qualitative Research | 15 | 2026 | 763 | 2.050 |
Why?
|
| Allostasis | 2 | 2025 | 10 | 1.730 |
Why?
|
| Public Health | 4 | 2026 | 188 | 1.690 |
Why?
|
| Humans | 129 | 2026 | 65830 | 1.670 |
Why?
|
| California | 30 | 2019 | 178 | 1.610 |
Why?
|
| Female | 91 | 2026 | 34420 | 1.560 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 6 | 2021 | 26 | 1.520 |
Why?
|
| Mental Health Services | 8 | 2025 | 306 | 1.510 |
Why?
|
| Male | 84 | 2026 | 31403 | 1.460 |
Why?
|
| Narcotic Antagonists | 8 | 2025 | 133 | 1.430 |
Why?
|
| Massachusetts | 14 | 2026 | 2158 | 1.390 |
Why?
|
| Prisons | 10 | 2026 | 121 | 1.240 |
Why?
|
| Young Adult | 30 | 2026 | 4882 | 1.200 |
Why?
|
| Drug and Narcotic Control | 5 | 2026 | 27 | 1.170 |
Why?
|
| Adult Survivors of Child Adverse Events | 2 | 2019 | 10 | 1.140 |
Why?
|
| Middle Aged | 45 | 2026 | 18498 | 1.110 |
Why?
|
| Central Nervous System Stimulants | 3 | 2026 | 66 | 1.100 |
Why?
|
| Naltrexone | 6 | 2025 | 91 | 1.060 |
Why?
|
| Criminal Law | 4 | 2023 | 87 | 1.060 |
Why?
|
| Sex Factors | 13 | 2025 | 995 | 1.050 |
Why?
|
| Veterans | 4 | 2022 | 770 | 1.030 |
Why?
|
| Health Status Disparities | 3 | 2017 | 147 | 1.020 |
Why?
|
| Veterans Health | 2 | 2018 | 147 | 1.000 |
Why?
|
| Alcoholism | 5 | 2017 | 329 | 0.950 |
Why?
|
| United States | 20 | 2026 | 8186 | 0.910 |
Why?
|
| Health Status | 3 | 2026 | 448 | 0.900 |
Why?
|
| Continuity of Patient Care | 1 | 2026 | 175 | 0.850 |
Why?
|
| Longitudinal Studies | 10 | 2026 | 1291 | 0.840 |
Why?
|
| HIV Infections | 6 | 2026 | 961 | 0.830 |
Why?
|
| Mental Recall | 1 | 2024 | 95 | 0.820 |
Why?
|
| Adolescent | 27 | 2026 | 6367 | 0.810 |
Why?
|
| Delayed-Action Preparations | 1 | 2024 | 120 | 0.810 |
Why?
|
| Cognitive Dysfunction | 2 | 2025 | 360 | 0.800 |
Why?
|
| Counseling | 2 | 2025 | 376 | 0.800 |
Why?
|
| Community Health Services | 2 | 2018 | 127 | 0.790 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 95 | 0.780 |
Why?
|
| Narcotics | 6 | 2017 | 57 | 0.780 |
Why?
|
| Community Mental Health Services | 6 | 2014 | 95 | 0.780 |
Why?
|
| Cannabis | 2 | 2021 | 54 | 0.780 |
Why?
|
| Attitude of Health Personnel | 3 | 2025 | 634 | 0.770 |
Why?
|
| Butterflies | 4 | 2024 | 34 | 0.760 |
Why?
|
| Amphetamine-Related Disorders | 7 | 2017 | 11 | 0.750 |
Why?
|
| Criminals | 3 | 2013 | 62 | 0.750 |
Why?
|
| Psoriasis | 2 | 2020 | 59 | 0.740 |
Why?
|
| Recidivism | 1 | 2022 | 30 | 0.680 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 2500 | 0.670 |
Why?
|
| Health Personnel | 4 | 2022 | 391 | 0.660 |
Why?
|
| Stress, Psychological | 1 | 2025 | 475 | 0.640 |
Why?
|
| Cardiovascular Diseases | 2 | 2025 | 877 | 0.630 |
Why?
|
| Caregivers | 2 | 2020 | 298 | 0.600 |
Why?
|
| Prediabetic State | 1 | 2020 | 54 | 0.600 |
Why?
|
| Conduct Disorder | 1 | 2019 | 24 | 0.600 |
Why?
|
| Patients | 1 | 2020 | 117 | 0.600 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2026 | 505 | 0.590 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 413 | 0.580 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 558 | 0.580 |
Why?
|
| Cocaine-Related Disorders | 5 | 2017 | 81 | 0.560 |
Why?
|
| Anxiety Disorders | 2 | 2019 | 201 | 0.550 |
Why?
|
| Musculoskeletal Pain | 1 | 2018 | 27 | 0.550 |
Why?
|
| Treatment Outcome | 25 | 2024 | 5834 | 0.550 |
Why?
|
| Methamphetamine | 6 | 2017 | 25 | 0.550 |
Why?
|
| Complementary Therapies | 1 | 2018 | 63 | 0.530 |
Why?
|
| Aged | 16 | 2025 | 15145 | 0.520 |
Why?
|
| Law Enforcement | 4 | 2017 | 26 | 0.510 |
Why?
|
| Alcohol-Related Disorders | 1 | 2017 | 37 | 0.490 |
Why?
|
| Life Change Events | 1 | 2017 | 66 | 0.490 |
Why?
|
| Personal Autonomy | 1 | 2016 | 71 | 0.480 |
Why?
|
| Interviews as Topic | 5 | 2026 | 535 | 0.470 |
Why?
|
| Chronic Pain | 1 | 2018 | 157 | 0.470 |
Why?
|
| Dementia | 2 | 2016 | 290 | 0.470 |
Why?
|
| Medicaid | 1 | 2020 | 379 | 0.460 |
Why?
|
| Mothers | 5 | 2014 | 281 | 0.440 |
Why?
|
| Health Services Needs and Demand | 3 | 2016 | 220 | 0.440 |
Why?
|
| Mental Health | 1 | 2018 | 363 | 0.430 |
Why?
|
| Homes for the Aged | 1 | 2016 | 166 | 0.430 |
Why?
|
| Program Evaluation | 7 | 2025 | 501 | 0.430 |
Why?
|
| Socioeconomic Factors | 3 | 2025 | 806 | 0.430 |
Why?
|
| Age Factors | 7 | 2025 | 1595 | 0.420 |
Why?
|
| Heroin Dependence | 3 | 2017 | 21 | 0.420 |
Why?
|
| Focus Groups | 5 | 2026 | 329 | 0.410 |
Why?
|
| Pandemics | 4 | 2022 | 691 | 0.410 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2019 | 119 | 0.400 |
Why?
|
| Social Environment | 1 | 2014 | 93 | 0.400 |
Why?
|
| Safety | 1 | 2014 | 142 | 0.400 |
Why?
|
| Intellectual Disability | 3 | 2026 | 177 | 0.390 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 2739 | 0.390 |
Why?
|
| Patient Dropouts | 3 | 2011 | 51 | 0.390 |
Why?
|
| Patient Safety | 1 | 2016 | 281 | 0.390 |
Why?
|
| Aphasia | 2 | 2024 | 48 | 0.380 |
Why?
|
| Perception | 1 | 2014 | 187 | 0.380 |
Why?
|
| Gender Identity | 3 | 2023 | 69 | 0.380 |
Why?
|
| Substance Abuse, Intravenous | 6 | 2016 | 84 | 0.380 |
Why?
|
| Residence Characteristics | 1 | 2014 | 230 | 0.370 |
Why?
|
| Policy | 2 | 2021 | 55 | 0.360 |
Why?
|
| Mental Disorders | 3 | 2015 | 827 | 0.340 |
Why?
|
| Employment | 2 | 2009 | 132 | 0.330 |
Why?
|
| Prevalence | 3 | 2020 | 1453 | 0.330 |
Why?
|
| Nursing Homes | 1 | 2016 | 701 | 0.320 |
Why?
|
| Recurrence | 6 | 2012 | 665 | 0.310 |
Why?
|
| Prospective Studies | 9 | 2019 | 3339 | 0.300 |
Why?
|
| Quality of Life | 4 | 2025 | 1266 | 0.300 |
Why?
|
| Cohort Studies | 10 | 2024 | 2651 | 0.300 |
Why?
|
| Self Report | 3 | 2025 | 395 | 0.300 |
Why?
|
| Patient Compliance | 5 | 2012 | 370 | 0.290 |
Why?
|
| Mandatory Programs | 1 | 2008 | 17 | 0.290 |
Why?
|
| Drug Users | 1 | 2008 | 29 | 0.280 |
Why?
|
| Databases as Topic | 1 | 2008 | 49 | 0.270 |
Why?
|
| Research Design | 2 | 2026 | 589 | 0.270 |
Why?
|
| Data Collection | 2 | 2006 | 384 | 0.260 |
Why?
|
| Referral and Consultation | 1 | 2011 | 447 | 0.260 |
Why?
|
| Skin | 3 | 2020 | 436 | 0.250 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 197 | 0.250 |
Why?
|
| Sex Distribution | 2 | 2017 | 252 | 0.250 |
Why?
|
| Secondary Prevention | 4 | 2013 | 165 | 0.240 |
Why?
|
| Comorbidity | 3 | 2021 | 1122 | 0.240 |
Why?
|
| Schizophrenia | 2 | 2022 | 279 | 0.240 |
Why?
|
| Indians, North American | 1 | 2006 | 28 | 0.240 |
Why?
|
| Depression | 2 | 2021 | 910 | 0.230 |
Why?
|
| Genetic Testing | 1 | 2026 | 144 | 0.220 |
Why?
|
| Time Factors | 8 | 2018 | 3777 | 0.220 |
Why?
|
| Social Support | 2 | 2026 | 394 | 0.220 |
Why?
|
| Nutrition Surveys | 1 | 2025 | 149 | 0.210 |
Why?
|
| Wings, Animal | 1 | 2024 | 29 | 0.210 |
Why?
|
| Pigmentation | 1 | 2024 | 25 | 0.210 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 3 | 2015 | 91 | 0.210 |
Why?
|
| Poetry as Topic | 1 | 2004 | 3 | 0.210 |
Why?
|
| Health Policy | 1 | 2026 | 191 | 0.210 |
Why?
|
| Age of Onset | 3 | 2017 | 174 | 0.200 |
Why?
|
| Incidence | 2 | 2025 | 1433 | 0.200 |
Why?
|
| Income | 1 | 2024 | 169 | 0.190 |
Why?
|
| Walking | 1 | 2025 | 248 | 0.190 |
Why?
|
| Privacy | 1 | 2023 | 10 | 0.190 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 230 | 0.190 |
Why?
|
| Health Services Research | 2 | 2023 | 265 | 0.180 |
Why?
|
| Social Stigma | 1 | 2023 | 79 | 0.180 |
Why?
|
| Inflammation | 2 | 2020 | 1198 | 0.180 |
Why?
|
| Grounded Theory | 1 | 2022 | 21 | 0.180 |
Why?
|
| Prescription Drug Diversion | 1 | 2022 | 6 | 0.180 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 439 | 0.180 |
Why?
|
| Risk Factors | 4 | 2018 | 5475 | 0.180 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 171 | 0.180 |
Why?
|
| Inpatients | 2 | 2021 | 322 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 378 | 0.170 |
Why?
|
| Rural Population | 1 | 2023 | 225 | 0.170 |
Why?
|
| Mood Disorders | 2 | 2019 | 79 | 0.170 |
Why?
|
| Anxiety | 2 | 2022 | 427 | 0.170 |
Why?
|
| Acute Pain | 1 | 2021 | 20 | 0.170 |
Why?
|
| Adaptation, Psychological | 3 | 2016 | 278 | 0.170 |
Why?
|
| Data Anonymization | 1 | 2020 | 1 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2020 | 22 | 0.160 |
Why?
|
| Neoplasms | 2 | 2024 | 1377 | 0.160 |
Why?
|
| Feeding and Eating Disorders | 1 | 2021 | 53 | 0.160 |
Why?
|
| Terminal Care | 1 | 2022 | 123 | 0.160 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 2790 | 0.160 |
Why?
|
| Risk-Taking | 3 | 2016 | 159 | 0.160 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 31 | 0.150 |
Why?
|
| Personality Disorders | 1 | 2019 | 20 | 0.150 |
Why?
|
| Social Media | 1 | 2022 | 129 | 0.150 |
Why?
|
| Health Equity | 1 | 2020 | 55 | 0.150 |
Why?
|
| Transgender Persons | 1 | 2020 | 68 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 56 | 0.140 |
Why?
|
| Sensory Receptor Cells | 1 | 2018 | 22 | 0.140 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 286 | 0.140 |
Why?
|
| Autistic Disorder | 1 | 2021 | 160 | 0.140 |
Why?
|
| Stroke | 2 | 2024 | 1225 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 319 | 0.130 |
Why?
|
| Child | 8 | 2024 | 4651 | 0.130 |
Why?
|
| Logistic Models | 3 | 2017 | 1274 | 0.130 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 51 | 0.130 |
Why?
|
| Financing, Government | 1 | 2017 | 31 | 0.120 |
Why?
|
| England | 1 | 2016 | 28 | 0.120 |
Why?
|
| Insulin | 1 | 2020 | 697 | 0.120 |
Why?
|
| Risk Management | 1 | 2016 | 37 | 0.120 |
Why?
|
| Siblings | 1 | 2016 | 41 | 0.120 |
Why?
|
| Behavioral Symptoms | 1 | 2016 | 18 | 0.120 |
Why?
|
| Motivation | 2 | 2009 | 298 | 0.120 |
Why?
|
| Diquat | 1 | 2016 | 1 | 0.120 |
Why?
|
| Environment | 1 | 2016 | 125 | 0.120 |
Why?
|
| Animals | 7 | 2024 | 21492 | 0.120 |
Why?
|
| Paraquat | 1 | 2016 | 13 | 0.120 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1044 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 183 | 0.120 |
Why?
|
| Herbicides | 1 | 2016 | 20 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 227 | 0.110 |
Why?
|
| Health Surveys | 1 | 2017 | 319 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3506 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2329 | 0.110 |
Why?
|
| Telemedicine | 1 | 2020 | 379 | 0.110 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 31 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1569 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 94 | 0.110 |
Why?
|
| Analgesics | 1 | 2016 | 102 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2016 | 145 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 406 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2017 | 301 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2017 | 274 | 0.110 |
Why?
|
| Olfactory Perception | 1 | 2014 | 3 | 0.110 |
Why?
|
| Population Density | 1 | 2014 | 13 | 0.110 |
Why?
|
| Glucose | 1 | 2017 | 478 | 0.110 |
Why?
|
| Internationality | 1 | 2014 | 46 | 0.110 |
Why?
|
| Olfaction Disorders | 1 | 2014 | 16 | 0.110 |
Why?
|
| Smell | 1 | 2014 | 29 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 549 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2016 | 203 | 0.100 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 17 | 0.100 |
Why?
|
| Vascular Resistance | 1 | 2014 | 47 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2025 | 1029 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 165 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2016 | 228 | 0.100 |
Why?
|
| Pain Management | 1 | 2016 | 174 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 244 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2014 | 169 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 738 | 0.100 |
Why?
|
| Psychotic Disorders | 1 | 2014 | 150 | 0.090 |
Why?
|
| Climacteric | 1 | 2012 | 4 | 0.090 |
Why?
|
| Interview, Psychological | 1 | 2012 | 79 | 0.090 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 308 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 146 | 0.090 |
Why?
|
| Parents | 1 | 2016 | 418 | 0.090 |
Why?
|
| Tobacco Use Cessation | 1 | 2012 | 32 | 0.090 |
Why?
|
| Disease Progression | 1 | 2016 | 1229 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 770 | 0.090 |
Why?
|
| Life Style | 1 | 2013 | 324 | 0.080 |
Why?
|
| Rehabilitation Centers | 1 | 2011 | 11 | 0.080 |
Why?
|
| Aging | 2 | 2015 | 784 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2024 | 2089 | 0.080 |
Why?
|
| Health Care Surveys | 2 | 2008 | 289 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2024 | 6955 | 0.080 |
Why?
|
| Phenotype | 2 | 2024 | 1236 | 0.080 |
Why?
|
| Genomics | 2 | 2023 | 387 | 0.080 |
Why?
|
| Mice | 2 | 2020 | 11185 | 0.070 |
Why?
|
| Infant | 3 | 2021 | 1718 | 0.070 |
Why?
|
| Crack Cocaine | 1 | 2008 | 7 | 0.070 |
Why?
|
| Utilization Review | 1 | 2008 | 32 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 864 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 389 | 0.060 |
Why?
|
| Accidents, Traffic | 1 | 2008 | 140 | 0.060 |
Why?
|
| Exercise | 1 | 2014 | 970 | 0.060 |
Why?
|
| Public Health Administration | 1 | 2006 | 22 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 5681 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2025 | 2115 | 0.060 |
Why?
|
| Ethics, Clinical | 1 | 2006 | 3 | 0.060 |
Why?
|
| Forensic Psychiatry | 1 | 2006 | 70 | 0.060 |
Why?
|
| Australia | 1 | 2026 | 131 | 0.060 |
Why?
|
| Confidentiality | 1 | 2006 | 58 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2006 | 442 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2026 | 153 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 40 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2004 | 40 | 0.050 |
Why?
|
| Harm Reduction | 1 | 2024 | 34 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2024 | 49 | 0.050 |
Why?
|
| Genome Size | 1 | 2023 | 1 | 0.050 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2023 | 2 | 0.050 |
Why?
|
| Marijuana Abuse | 2 | 2017 | 24 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2025 | 746 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2024 | 132 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2024 | 83 | 0.050 |
Why?
|
| Psycholinguistics | 1 | 2023 | 36 | 0.050 |
Why?
|
| Hospitals, Psychiatric | 1 | 2023 | 58 | 0.050 |
Why?
|
| Outpatients | 1 | 2004 | 143 | 0.050 |
Why?
|
| Reproductive Isolation | 1 | 2022 | 11 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2004 | 235 | 0.050 |
Why?
|
| Genetic Speciation | 1 | 2022 | 15 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2022 | 20 | 0.050 |
Why?
|
| Language | 1 | 2024 | 155 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 218 | 0.050 |
Why?
|
| Neon | 1 | 2022 | 1 | 0.050 |
Why?
|
| Phylogeny | 1 | 2023 | 399 | 0.040 |
Why?
|
| Death | 1 | 2022 | 33 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2023 | 169 | 0.040 |
Why?
|
| Muscarinic Antagonists | 1 | 2022 | 33 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 256 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2022 | 129 | 0.040 |
Why?
|
| State Government | 1 | 2021 | 32 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 150 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2021 | 60 | 0.040 |
Why?
|
| DNA Transposable Elements | 1 | 2022 | 160 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 828 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2020 | 39 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 67 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 344 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2022 | 351 | 0.040 |
Why?
|
| Health Services | 1 | 2020 | 80 | 0.040 |
Why?
|
| Gene Expression | 1 | 2022 | 856 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2021 | 166 | 0.040 |
Why?
|
| Drosophila | 1 | 2022 | 480 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 514 | 0.040 |
Why?
|
| TRPA1 Cation Channel | 1 | 2018 | 5 | 0.040 |
Why?
|
| Reactive Nitrogen Species | 1 | 2018 | 9 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2018 | 11 | 0.040 |
Why?
|
| Substance P | 1 | 2018 | 43 | 0.040 |
Why?
|
| Diterpenes | 1 | 2018 | 13 | 0.040 |
Why?
|
| Denervation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Hypertension | 1 | 2024 | 618 | 0.040 |
Why?
|
| TRPV Cation Channels | 1 | 2018 | 22 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.030 |
Why?
|
| Hospitalization | 1 | 2025 | 1404 | 0.030 |
Why?
|
| Chromatin | 1 | 2022 | 643 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 65 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2011 | 606 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 238 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.030 |
Why?
|
| New York City | 1 | 2016 | 96 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2016 | 60 | 0.030 |
Why?
|
| Crime Victims | 1 | 2017 | 39 | 0.030 |
Why?
|
| Accidents, Occupational | 1 | 2016 | 49 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 200 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 192 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2015 | 67 | 0.030 |
Why?
|
| Homeostasis | 1 | 2017 | 383 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2015 | 104 | 0.030 |
Why?
|
| Seizures | 1 | 2015 | 141 | 0.030 |
Why?
|
| Pregnancy | 2 | 2011 | 2401 | 0.030 |
Why?
|
| Parkinson Disease | 1 | 2015 | 135 | 0.020 |
Why?
|
| Pediatrics | 1 | 2016 | 265 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2016 | 322 | 0.020 |
Why?
|
| British Columbia | 1 | 2012 | 5 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 105 | 0.020 |
Why?
|
| New York | 1 | 2012 | 144 | 0.020 |
Why?
|
| Prescription Drug Misuse | 1 | 2011 | 20 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 296 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 178 | 0.020 |
Why?
|
| Reward | 1 | 2011 | 89 | 0.020 |
Why?
|
| China | 1 | 2011 | 181 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 1438 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 859 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 192 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 382 | 0.020 |
Why?
|
| Unsafe Sex | 1 | 2008 | 27 | 0.020 |
Why?
|
| Intention | 1 | 2008 | 74 | 0.020 |
Why?
|
| Substance Abuse Detection | 1 | 2007 | 39 | 0.020 |
Why?
|
| Episode of Care | 1 | 2006 | 8 | 0.010 |
Why?
|
| Efficiency, Organizational | 1 | 2006 | 98 | 0.010 |
Why?
|
| Patient Admission | 1 | 2006 | 200 | 0.010 |
Why?
|
| Residential Treatment | 1 | 2004 | 34 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2004 | 318 | 0.010 |
Why?
|